Close Menu

NEW YORK (GenomeWeb) – NeoGenomics announced today its participation as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice, or NCI-MATCH, precision medicine cancer treatment clinical trial.

As a designated sequencing lab for the trial, the Fort Myers, Florida-based company will use its NeoType Discovery Panel to identify patients who may be eligible for treatment of their tumor types at clinical sites participating in NCI-MATCH. The panel assesses 320 cancer-related genes in solid tumors, hematologic malignancies, and advanced sarcomas.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.